These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37738542)

  • 1. Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.
    Steenbruggen TG; Wolf DM; Thijssen B; Sanders J; Cornelissen S; Salgado R; Mittempergher L; Bhaskaran R; Broeks A; Lips EH; Siesling S; Sonke GS; Horlings HM; van 't Veer LJ
    JCO Precis Oncol; 2023 Sep; 7():e2200670. PubMed ID: 37738542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
    Steenbruggen TG; Schaapveld M; Horlings HM; Sanders J; Hogewoning SJ; Lips EH; Vrancken Peeters MT; Kok NF; Wiersma T; Esserman L; van 't Veer LJ; Linn SC; Siesling S; Sonke GS
    JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in patients with oligometastatic breast cancer - A systematic review.
    van Ommen-Nijhof A; Steenbruggen TG; Schats W; Wiersma T; Horlings HM; Mann R; Koppert L; van Werkhoven E; Sonke GS; Jager A
    Cancer Treat Rev; 2020 Dec; 91():102114. PubMed ID: 33161237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
    Nagasaki E; Kudo R; Tamura M; Hayashi K; Uwagawa T; Kijima Y; Nogi H; Takeyama H; Suzuki M; Nishikawa M; Yano S; Kobayashi T
    Breast Cancer; 2021 Sep; 28(5):1051-1061. PubMed ID: 33840010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.
    Mimoto R; Kobayashi T; Imawari Y; Kamio M; Kato K; Nogi H; Toriumi Y; Hirooka S; Uchida K; Takeyama H
    Breast Cancer Res Treat; 2014 Sep; 147(2):317-24. PubMed ID: 25156580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
    Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
    Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and prognostic factors in oligometastatic breast cancer.
    van Ommen-Nijhof A; Steenbruggen TG; Capel L; Vergouwen M; Vrancken Peeters MT; Wiersma TG; Sonke GS
    Breast; 2023 Feb; 67():14-20. PubMed ID: 36549169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes.
    Glemarec G; Lacaze JL; Cabarrou B; Aziza R; Jouve E; Zerdoud S; De Maio E; Massabeau C; Loo M; Esteyrie V; Ung M; Dalenc F; Izar F; Chira C
    Breast; 2023 Feb; 67():102-109. PubMed ID: 36709639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution.
    Lacaze JL; Chira C; Glemarec G; Monselet N; Cassou-Mounat T; De Maio E; Jouve E; Massabeau C; Brac de la Perrière C; Selmes G; Ung M; Nicolai V; Cabarrou B; Dalenc F
    Breast Cancer Res Treat; 2023 Apr; 198(3):463-474. PubMed ID: 36790573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
    Bamias A; Stenzl A; Brown SL; Albiges L; Babjuk M; Birtle A; Briganti A; Burger M; Choudhury A; Colecchia M; De Santis M; Fanti S; Fonteyne V; Gallucci M; Rivas JG; Huddart R; Junker K; Kroeze S; Loriot Y; Merseburger A; Montironi R; Necchi A; Oing C; Oldenburg J; Ost P; Pinkawa M; Ribal MJ; Rouprêt M; Thoeny H; Zilli T; Hoskin P
    Eur Urol; 2023 Oct; 84(4):381-389. PubMed ID: 37217391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SABR in oligometastatic breast cancer: Current status and future directions.
    Stewart R; White M; Tan J; Siva S; Karroum L; David S
    Breast; 2021 Dec; 60():223-229. PubMed ID: 34739890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.
    Yardley DA; Tripathy D; Brufsky AM; Rugo HS; Kaufman PA; Mayer M; Magidson J; Yoo B; Quah C; Ulcickas Yood M
    Br J Cancer; 2014 May; 110(11):2756-64. PubMed ID: 24743708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligometastatic breast cancer: An institutional analysis.
    Gogia A; S Deo SV; Sharma DN; Mathur S
    Indian J Cancer; 2022; 59(2):257-262. PubMed ID: 35946184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2-Positive Metastatic Breast Cancer in Manitoba.
    McAndrew EN; Graham J; Dufault B; Desautels DN; Kim CA
    Am J Clin Oncol; 2024 Mar; 47(3):122-127. PubMed ID: 38047455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
    Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
    Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligometastatic Breast Cancer: How to Manage It?
    Barberi V; Pietragalla A; Franceschini G; Marazzi F; Paris I; Cognetti F; Masetti R; Scambia G; Fabi A
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34207648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.
    Harano K; Lei X; Gonzalez-Angulo AM; Murthy RK; Valero V; Mittendorf EA; Ueno NT; Hortobagyi GN; Chavez-MacGregor M
    Breast Cancer Res Treat; 2016 Sep; 159(2):367-74. PubMed ID: 27522517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 19. Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature.
    Makhlin I; Fox K
    Curr Oncol Rep; 2020 Feb; 22(2):15. PubMed ID: 32025905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining Oligometastatic Bladder Cancer: A Systematic Review.
    Bamias A; Stenzl A; Zagouri F; Andrikopoulou A; Hoskin P
    Eur Urol Open Sci; 2023 Sep; 55():28-37. PubMed ID: 37662704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.